THinc is a company of regulatory affairs, medical writing, and submission services professionals with a proven track record of success in the pharmaceutical industry. THinc was established as a privately held consulting firm in 1995 to expedite the development and approval of new medicines. Our clientele range from emerging, privately held biopharmaceutical companies to Fortune 500 pharmaceutical companies.

Therapeutic Areas of Expertise

  • Cancer (head and neck, ovarian, breast, non-small-cell lung, small-cell lung, esophageal, prostate, hepatocellular, basal cell, and squamous cell cancer; melanoma; Kaposi's sarcoma; non-Hodgkin's lymphoma)
  • Cardiovascular disease (angina, hypertension, pulmonary arterial hypertension)
  • Cerebrovascular diseases (transient ischemic attack, stroke)
  • Dermatologic diseases (atopic dermatitis, condylomata acuminata)
  • Gastrointestinal diseases (irritable bowel syndrome both diarrhea- and
    constipation-predominant, hepatic encephalopathy, ulcerative colitis,
    celiac disease, UCDs)
  • Immunological diseases (transplant rejection agents)
  • Infectious diseases (bacterial, fungal, and viral infections)
  • Neurological diseases (Parkinson’s disease, pain, migraine)
  • Ophthalmic diseases (diabetic macular edema, wet age-related macular degeneration, and dry eye syndrome)
  • Pulmonary disease (idiopathic pulmonary fibrosis, cystic fibrosis)
THinc